TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06798454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVT201
Description: Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor.~PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells.~IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections.~PVT201 will be administered intravenously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will be administered normal saline IV.
Study: NCT06335537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: Urocit-K 30 mEQ orally taken in the morning and evening.
Study: NCT05633420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyramax
Description: Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)
Study: NCT06335537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: Urocit-K 30 mEQ orally taken in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
Study: NCT05509582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Subjects will receive fostamatinib at the same dose as the dose they receive at the time of rollover. The dose could be reduced to 100mg daily, 150 mg daily, 100 mg twice a day if a dose-limiting adverse event occurred. After the initial 12 weeks on the extended access (total of 24 weeks of treatment), subjects will have the option to start tapering fostamatinib if they are maintaining hematologic recovery. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response, defined as Hb\<9g/dL and/or PLT\< 30 X 10\^9/L can increase their dose to next higher dose. Once count stabilization again occurs, a slow dose reduction to next lowest dose (100mg or 150mg) can be performed to identify the lowest dose necessary to keep counts over these thresholds.
Study: NCT04770012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
Study: NCT06312020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration
Study: NCT04770012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
Study: NCT06312020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-1116
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Administration
Study: NCT06794983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person visit with study team member
Description: Participants meet with a study team member before they are released from prison.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person visit with NCM
Description: Participants meet with a NCM before they are released from prison.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls and texts
Description: Study team member calls and texts participants after they are released from prison.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls and texts - NCM
Description: Nurse case manager calls and texts participants after they are released from prison.
Study: NCT06799052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcervical single-balloon catheter
Description: A single-balloon (Foley) catheter will be placed through the cervix and filled to 30cc of water or saline. The balloon will remain in the participant until their procedure, usually 3-4 hours, or earlier if it falls out on its own.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic osmotic dilators
Description: Dilators will be maintained in the cervix between 3-4 hours, during which each dilator rod will swell several times its initial dried diameter.
Study: NCT06799559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-6mg QLM1016
Description: 3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-20 mg Aripiprazole oral solution film
Description: 10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
Study: NCT06800183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four-Chamber Tartrazine Patch across 3 Body Sites
Description: This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
Study: NCT06799845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX101
Description: ATX101 bupivacaine implants, total of 1,500 mg into the surgical site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine hydrochloride
Description: bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
Study: NCT06798545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound with navigation system
Description: Use of the EZ-EUS navigation system during the procedure
Study: NCT06798909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir (Pre-emptive CMV Therapy)
Description: Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir CMV Prophylaxis
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.
Study: NCT06798597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health4Life app
Description: Health4Life is a program based on the anticipatory guidance approach aiming to support parents create healthy lifestyle behaviours starting in early infancy. The intervention consists of ten themes over a 16 month period and incorporates interactive features such as quizzes.
Study: NCT06799351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (placebo)
Description: Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study: NCT06800053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS ON US
Description: This intervention will include 5 sessions cover 5 core content areas, represented by the acronym FOCUS. Family involvement (F) Outlook and meaning (O) Coping effectiveness (C) Uncertainty reduction (U) Symptom management (S) Content from every area is presented in the 3 longer in-depth sessions and reinforced in the 2 shorter check-in sessions. FOCUS encourages participants to work as a team, communicate openly, and support one another, and uses skill building (e.g., stress reduction techniques, healthy behaviors), education (e.g., symptom trajectories, information gathering), and problem-solving therapy to address here-and-now issues that impact QOL. The intervention is flexible, allowing more attention to be spent on issues relevant to particular patients/caregivers.
Study: NCT06799377

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restricted Activity Reccomendations
Description: Patients in this respective group will be given restricted activity recommendations over the casting period. They will be told Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the restricted activity group. We ask that you limit sprinting, jumping, and organized sports during the time of cast immobilization. As a rule of thumb, we recommend feet on the floor activities while playing and avoiding playgrounds and gym class if possible. While it is not realistic to restrict a young child entirely, do your best to avoid strenuous or intense exercise until cleared by your physician or nurse practitioner

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full Activity/Limited Activity Reccomendations
Description: Patients in this respective group will be allowed to engage in most activities. They will be read Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the activity as tolerated group. Your child may participate in all desired activities except contact sports. Your child does not need to increase his/her activity level but should participate in activities as they feel comfortable doing so. Sprinting, jumping, and organized sports are acceptable as long as your child is not experiencing pain. Your child may use playgrounds and participate in gym class as desired. Do your best to avoid restricting your child from activities unless they are experiencing pain or you have concerns about their safety.
Study: NCT06798753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion Balloon Catheter
Description: The occlusion balloon catheter (OBC) is a type of ureteral catheter equipped with a small inflatable balloon at its tip. When inflated, the balloon can help prevent the migration of stone fragments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5FR Ureteral Catheter
Description: The 5FR ureteral catheter (5FR-UC) is an open-ended small-caliber tube inserted at the beginning of PCNL to facilitate visualization of the collecting system using fluoroscopy and assist with renal access.
Study: NCT06564142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povetacicept
Description: Subcutaneous injection administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to Povetacicept)
Description: Placebo matched to Povetacicept subcutaneous injection administration.
Study: NCT06799533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046031
Description: Given into the vein (IV; intravenous)
Study: NCT06545942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOMA-313
Description: MOMA-313 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOMA-313
Description: MOMA-313 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally
Study: NCT06563128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clearfil Majesty Posterior
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnichroma Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zen Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vittra Aps Unique Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charisma Diamond Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study: NCT05710536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formulation X
Description: This formulation containing stem cell secretome and liquorice root extract
Study: NCT06461897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablet or Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablet or Oral Solution
Study: NCT06017700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy Group
Description: IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
Study: NCT06259032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical alignment
Description: Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional alignment
Description: Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
Study: NCT06302426

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study: NCT06461897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous Injection
Study: NCT06071221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthy educational program + peer coaching
Description: The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy educational program
Description: Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
Study: NCT05593107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]N188
Description: 68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study: NCT05687032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV
Study: NCT05904080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05304767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study: NCT06566820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aroxybutynin and Atomoxetine
Description: Fixed Dose Combination